Sun Pharma Inks Pact with LIB Therapeutics to Sell LDL-C Drug

Sun Pharma inks pact with LIB Therapeutics to sell LDL-C drug

Sun Pharma inks exclusive licensing with LIB Therapeutics to commercialize lerodalcibep worldwide (excluding U.S. and China) for LDL-C reduction.

Sun Pharma inks global licensing pact with LIB Therapeutics for cholesterol drug Lerodalcibep

Lerodalcibep is a once-monthly PCSK9 inhibitor used to reduce low-density lipoprotein cholesterol (LDL-C) and treat adult patients with hypercholesterolaemia and mixed dyslipidaemia

Sun Pharma to sell cholesterol control drug worldwide under license from US-based LIB Therapeutics - Hello Entrepreneurs

Mumbai, September 28: Pharma major Sun Pharmaceuticals has entered into an exclusive lincensing agreement with US based LIB Therapeutics to develop and commercialise lerodalcibep, a third-generation PCSK9 inhibitor designed to treat bad cholesterol. This move grants Sun Pharma exclusive rights to the drug in all global markets except China and the US, with the therapy […] <p>The post Sun Pharma to sell cholesterol control drug worldwide under li…

LIB Therapeutics and Sun Pharma announce manufacturing agreement for Lerodalcibep, a PCSK9 Inhibitor

Lerodalcibep is approved in the EU under the brand name Lyrokaul for the treatment of adult patients with hypercholesterolaemia and mixed dyslipidaemia

Sun Pharma Bags Global Rights to Cholesterol Drug Lerodalcibep

Sun Pharma shares hit a day high of Rs 1,855 on NSE on 28 September, after it signed a global licensing deal for a cholesterol drug. In an exchange filing, Sun Pharmaceutical Industries Ltd said it has signed an exclusive licensing, commercialisation and manufacturing agreement with LIB Therapeutics Inc for...

Sun Pharma Inks Global Licensing Deal With LIB Therapeutics For PCSK9 Inhibitor

Sun Pharmaceutical Industries Limited announced on Monday an exclusive licensing agreement with LIB Therapeutics Inc. to commercialise and manufacture lerodalcibep, a PCSK9 inhibitor, outside the US and China.